Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering
Drug Target Review
JUNE 6, 2023
Difficult-to-treat and rare, complicated cancers remain a perplexing challenge for IO researchers. Research has shown that these immune system proteins have the ability to trigger anti-cancer immune pathways. Currently he is Alkermes’ Oncology Fellow and Head of a Oncology Preclinical Research at the company. References: M; LWR.
98 
Let's personalize your content